Your session is about to expire
Saxenda vs Victoza
Introduction
For patients dealing with obesity or Type 2 diabetes, certain medications that alter the body's insulin production and appetite regulation can assist in weight management and blood sugar control. Saxenda and Victoza are two such drugs that are prescribed for these conditions. They both act on receptors of a hormone called glucagon-like peptide-1 (GLP-1) but have different applications.
Saxenda is primarily used for weight loss, approved to treat obese adults or overweight individuals who also have weight-related medical problems. It works by mimicking a hormone found in the intestines which signals the brain that stomach is full.
Victoza, on the other hand, is utilized mainly to improve blood sugar control in adults with Type 2 diabetes. It acts by stimulating natural insulin production when high levels of glucose are present while simultaneously inhibiting inappropriate glucagon release.
Saxenda vs Victoza Side By Side
| Attribute | Saxenda | Victoza |
|---|---|---|
| Brand Name | Saxenda | Victoza |
| Contraindications | Should not be taken with certain diabetes medications like insulin or sulfonylureas without dosage adjustments to avoid hypoglycemia. Not recommended for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). | Should not be used in individuals with type 1 diabetes or those with diabetic ketoacidosis. Not recommended for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). |
| Cost | Approximately $1300 for one pen (18mg/3ml), which lasts about 30 days | Roughly $800 per carton (containing three pens of 18 mg/3 ml), amounting to a daily cost of about $9 at the maximum recommended dosage. |
| Generic Name | Liraglutide | Liraglutide |
| Most Serious Side Effect | Possible thyroid tumors, including cancer; pancreatitis; signs of allergic reactions; rapid heart rate and palpitations; gallbladder problems; low blood sugar (hypoglycemia). | Signs of allergic reactions; kidney problems; pancreatitis; low blood sugar; possible thyroid tumors including cancer. |
| Severe Drug Interactions | Not specified, but caution advised with diabetes medications to avoid hypoglycemia. | Not specified, but caution advised with diabetes medications to avoid hypoglycemia. |
| Typical Dose | Starts at 0.6 mg/day, increased weekly by 0.6 mg until a dosage of 3.0 mg/day is reached. | Initiated at 0.6 mg/day, can be increased to 1.2 mg/day after one week, and further to a maximum of 1.8 mg/day if necessary and well-tolerated. |
What is Saxenda?
Liraglutide is the generic name for both Saxenda and Victoza, two medications that were developed by Novo Nordisk. Although they contain the same active ingredient, these drugs are used to treat different conditions and have distinct FDA approvals. Saxenda was approved in 2014 as a weight loss medication for individuals with a body mass index of over 30, or over 27 if there are other weight-related health complications present like hypertension or type-2 diabetes. On the other hand, Victoza was approved in 2010 for managing type-2 diabetes. The primary function of Liraglutide (in either form) is to mimic GLP-1 (Glucagon-Like Peptide), a natural hormone that controls appetite and regulates blood sugar levels. Both medications can cause side effects such as nausea or upset stomach; however, due to its higher dosage range, Saxenda may lead to more pronounced side effects than Victoza.
What conditions is Saxenda approved to treat?
Saxenda and Victoza, both containing the active ingredient liraglutide, have different FDA-approved uses:
- Saxenda is approved for chronic weight management in adults with a body mass index (BMI) of 30 or more (obese), or 27 or more (overweight) in the presence of at least one weight-related condition such as high blood pressure, type 2 diabetes mellitus, or high cholesterol.
- Victoza is intended to improve glycemic control in adults with type 2 diabetes mellitus when used alongside diet and exercise.
How does Saxenda help with these illnesses?
Saxenda aids in weight management by mimicking the effects of a hormone called glucagon-like peptide-1 (GLP-1). This hormone, naturally produced in our bodies, helps to regulate appetite and food intake. Saxenda works by binding to GLP-1 receptors in the brain - particularly within an area known as the hypothalamus which is responsible for regulating hunger and satiety. By activating these receptors, Saxenda can promote feelings of fullness even when we have eaten less than usual. As a result, it can help overweight or obese individuals reduce their calorie consumption and lose weight. It's important to note that while both Saxenda and Victoza contain liraglutide (a GLP-1 receptor agonist), they are used for different purposes: Victoza is primarily used for managing type 2 diabetes whereas Saxenda is specifically approved for weight management.
What is Victoza?
Victoza is a brand name for liraglutide, which is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist. This means that it acts on the same receptors as GLP-1, a hormone in your body that helps control blood sugar levels by promoting insulin release and inhibiting glucagon production when glucose levels are high. Liraglutide was first approved by the FDA in 2010 for use in managing type 2 diabetes mellitus.
Unlike Saxenda, Victoza is not intended specifically as a weight loss medication, but rather to help manage blood glucose levels. However, because its mechanism of action involves slowing down gastric emptying and making you feel full longer after meals (similar to Saxenda), some patients may experience weight loss while taking this medication.
It's worth noting though that like with all medications there can be side effects; common ones include nausea or vomiting especially at the beginning of treatment. It does not cause drowsiness and is less likely to cause sexual dysfunction compared to certain other diabetes treatments - similar to how Wellbutrin doesn't have these effects compared with Prozac.
What conditions is Victoza approved to treat?
Victoza has been approved by the FDA for managing:
- Type 2 diabetes as an adjunct to diet and exercise
- Reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
Remember, Victoza is not a substitute for insulin. It should not be used in individuals with type 1 diabetes or those with diabetic ketoacidosis.
How does Victoza help with these illnesses?
Glucagon-like peptide-1 (GLP-1) is a hormone in the body that plays crucial roles in regulating blood sugar levels, slowing gastric emptying and reducing appetite. Victoza works by mimicking the functions of GLP-1, thereby helping to control blood glucose levels, particularly after meals. Its action on slowing down gastric emptying also results in patient feeling fuller for longer periods, which can assist with weight management. It's primarily prescribed to help manage Type 2 diabetes but may have off-label use for weight loss as well. Since it does not significantly affect insulin production or cause low blood sugar (hypoglycemia), it is often preferred when patients do not respond well to other antidiabetic medications such as metformin or sulfonylureas. Compared to Saxenda, another GLP-1 receptor agonist designed specifically for weight management, Victoza has been around longer and its effects are more extensively studied especially regarding long-term safety and efficacy.
How effective are both Saxenda and Victoza?
Both liraglutide (Saxenda) and liraglutide (Victoza) have established histories of success in treating patients with obesity and type 2 diabetes respectively, though they were approved by the FDA for these uses several years apart. Since they are both forms of the same medication but used for different purposes, their prescription depends on the patient's specific needs. The effectiveness of Saxenda in achieving weight loss was directly studied in a double-blind clinical trial in 2015; it showed significantly greater efficacy than placebo at managing obesity as well as an acceptable safety profile. In this study, various metrics such as body mass index reduction and waist circumference decrease favored Saxenda over placebo.
A review conducted in 2014 concluded that Victoza is effective from the first week of treatment at controlling blood glucose levels, its side effect profile is generally favorable compared to other antidiabetic drugs, and it can be well-tolerated even by elderly populations or those with kidney disease. This study also noted that Victoza has become one of the most widely prescribed glucagon-like peptide-1 receptor agonists across the globe due to its once-daily dosing convenience.
In contrast to Saxenda’s use for weight management, Victoza is usually considered after metformin fails or cannot be tolerated due to side effects when treating type 2 diabetes. Furthermore, while there exists robust data supporting Victoza's role as monotherapy or add-on therapy for managing blood sugar levels, research confirming Saxenda's efficacy solely as an anti-obesity agent without lifestyle modification remains scarce. Nonetheless, due to their unique pharmacology shared between them - primarily slowing gastric emptying and promoting satiety - both may be optimal treatments depending on individual patient circumstances.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Saxenda typically prescribed?
Injectable dosages of Saxenda for weight management start at 0.6 mg/day, and should be increased weekly by 0.6 mg until a dosage of 3.0 mg/day is reached. However, studies have indicated that even lower doses can assist with weight loss in some people. For Victoza, when used to manage type-2 diabetes, the starting dose is also 0.6 mg/day but it's typically increased after one week to 1.2 mg per day based on how well the patient's blood sugar levels are controlled; if necessary it may be further increased after another week to a maximum of 1.8mg/day dose depending on individual response and tolerability.
At what dose is Victoza typically prescribed?
Victoza treatment is typically initiated at a dosage of 0.6 mg/day, injected subcutaneously (under the skin). After one week, this dose can be increased to 1.2 mg/day based on how the patient's body responds to it. If necessary and well-tolerated, the dosage may further be raised to a maximum of 1.8 mg/day after another week or so. The doses are taken once daily irrespective of meals and should ideally be administered around the same time each day for consistency in maintaining blood sugar levels. It is always recommended that any changes in dosages or medication schedules should only occur under your doctor's supervision.
What are the most common side effects for Saxenda?
Common side effects of Saxenda and Victoza include:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Headache
- Decreased appetite (anorexia)
- Dyspepsia (burning, discomfort, or pain in the digestive tract)
- Abdominal Pain
- Indigestion
- Fatigue (general weakness) -Dizziness -Increased lipase levels
Please note that these medications can sometimes cause more serious side effects. Speak with your healthcare provider if you experience any unusual symptoms while taking either of these medications.
Are there any potential serious side effects for Saxenda?
In rare cases, Saxenda can cause serious side effects which include:
- Indications of possible thyroid tumors: lump or swelling in your neck, trouble swallowing, hoarseness, shortness of breath.
- Pancreatitis symptoms such as severe stomach pain that may move to your back and accompanied by vomiting.
- Signs of allergic reactions like skin rashes or hives; rapid heartbeat; difficulty breathing or swallowing; swelling on the face, lips, tongue or throat.
- Rapid heart rate and palpitations
- Gallbladder problems symptoms including right upper abdominal pain discomfort or tenderness
- Low blood sugar (hypoglycemia) which includes headache, drowsiness weakness irritability hunger fast heartbeat confusion trembling sweating
If you experience any kind of these side effects while using Saxenda stop taking it immediately and consult with your healthcare provider.
Please note that this list is not exhaustive. Always follow the guidelines provided by a healthcare professional when starting a new medication regimen.
What are the most common side effects for Victoza?
Victoza, an injectable prescription medicine, can sometimes cause the following side effects:
- Nausea, vomiting and diarrhea
- Decreased appetite leading to weight loss
- Headache or dizziness
- Upset stomach or indigestion
- Fatigue or weakness
- Rash or itching at the site of injection
- Fast heartbeat could be a sign of serious complications.
However, it's crucial to note that most people do not experience all these side effects with Victoza. If any do occur and persist beyond a few days after starting treatment—or if you have concerns about them—it's essential to consult your healthcare provider immediately.
Are there any potential serious side effects for Victoza?
Victoza, while generally considered safe and effective for managing Type 2 diabetes or preventing heart diseases, can occasionally lead to serious side effects. It's important to be aware of these potential symptoms:
- Signs of an allergic reaction such as hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
- Kidney problems - little or no urination; painful or difficult urination; swelling in your feet or ankles; feeling tired or short of breath.
- Pancreatitis - severe pain in your upper stomach spreading to your back, nausea and vomiting.
- Low blood sugar - headache, hunger, sweating, irritability dizziness and fast heart rate
- Possible thyroid tumors including cancer: lump on the neck with trouble swallowing/breathing.
If any of these occur after taking Victoza you should stop using the medication immediately and contact a healthcare professional promptly.
Contraindications for Saxenda and Victoza?
Both Saxenda and Victoza, like other glucagon-like peptide-1 (GLP-1) receptor agonists, may cause side effects in some people. If you experience severe nausea, vomiting, or signs of a kidney problem such as changes in urine output or swelling ankles/feet, seek immediate medical attention.
Neither Saxenda nor Victoza should be taken if you are currently taking, or have recently taken certain medications for diabetes such as insulin or sulfonylureas. Always inform your doctor about all the medicines you are taking; these specific diabetic drugs may require adjustments to dosage when combined with either Saxenda or Victoza to avoid hypoglycemia (low blood sugar).
Also important is that both these medications can lead to thyroid tumors including cancer especially if there's family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Regular check-ups and monitoring is necessary while on these treatments.
How much do Saxenda and Victoza cost?
For the brand name versions of these drugs:
- The price of one Saxenda pen (which contains 18mg/3ml) averages around $1300, which works out to approximately $43/day given that each pen lasts about 30 days.
- Conversely, Victoza costs roughly $800 per carton (containing three pens of 18 mg/3 ml), amounting to a daily cost of about $9 if you're using up to the recommended maximum dosage.
Hence, if you are utilizing higher dosages for Victoza or Saxenda, then brand-name Victoza is less costly on a per-day treatment basis. It's crucial to bear in mind that cost should not be your primary determining factor when deciding between these medications.
Unfortunately, there isn't any generic version available for either Saxenda or Victoza currently; thus prices remain relatively high and similar across pharmacies.
Popularity of Saxenda and Victoza
Liraglutide, in generic form as well as brand names such as Victoza, was estimated to have been prescribed to about 1.7 million people in the US in 2020. Liraglutide accounted for just over 11% of glucagon-like peptide-1 receptor agonist prescriptions in the US. However, it appears to be one of the most-common “atypical” drugs (not classified as an insulin or other broad class of diabetes medications). Liraglutide has been generally increasing in prevalence since its introduction.
Saxenda, a higher dose formulation of liraglutide specifically designed for weight loss treatment rather than blood sugar control like Victoza, was prescribed to approximately 800 thousand people in the USA in 2020. In the US, Saxenda accounts for a significant portion of non-surgical obesity treatment prescriptions and is continuing to grow steadily due to rising rates of obesity and increased acceptance from insurance providers. The prevalence and usage rate growth trajectory suggests that it could soon rival Victoza's prescription numbers.
Conclusion
Both Saxenda (liraglutide) and Victoza (liraglutide) are forms of the same active ingredient, liraglutide, a glucagon-like peptide-1 receptor agonist. They are used in patients with type 2 diabetes and obesity. Their mechanism of action involves promoting insulin secretion and suppressing glucagon production, which helps control blood sugar levels. While they share the same active substance, these drugs have different indications: Saxenda is specifically approved for weight management in adults with a BMI over 30 or those with at least one weight-related health condition such as hypertension or type 2 diabetes who have a BMI over 27; Victoza is indicated to improve glycemic control in adult patients with type 2 diabetes.
Neither medication has an available generic form yet, which can impact cost considerations for out-of-pocket paying patients. The dosages of each drug differ significantly due to their respective therapeutic uses - Saxenda's higher dose targets weight loss while Victoza's lower dose aims at managing blood glucose levels.
The side effects profile is relatively similar between both medications since they contain the same active ingredient, including nausea, diarrhea and decreased appetite being common adverse reactions. Close monitoring is required when starting treatment due to potential thyroid tumor risk associated with liraglutide use. Patients should immediately seek medical help if they experience symptoms like lump or swelling in neck area or difficulty swallowing.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Clements, J. N., & Shealy, K. M. (2015, May 18). Liraglutide. Annals of Pharmacotherapy. SAGE Publications.http://doi.org/10.1177/1060028015586806
- Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., & le Roux, C. W. (2016, March). Exposure–response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obesity and Metabolism. Wiley.http://doi.org/10.1111/dom.12639
- Scott, L. J. (2014, November 4). Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-014-0321-6
- Usui, R., Sakuramachi, Y., Seino, Y., Murotani, K., Kuwata, H., Tatsuoka, H., … Yabe, D. (2017, December 13). Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β‐cell function and the achievement of the glycated hemoglobin target 1 year after initiation. Journal of Diabetes Investigation. Wiley.http://doi.org/10.1111/jdi.12773
- Gross, B. (2012, December 2). Clinical Pearls for Initiating and Utilizing Liraglutide in Patients With Type 2 Diabetes. Journal of Pharmacy Practice. SAGE Publications.http://doi.org/10.1177/0897190012465985
- Lee, P. H., Stockton, M. D., & Franks, A. S. (2011, April). Acute Pancreatitis Associated with Liraglutide. Annals of Pharmacotherapy. SAGE Publications.http://doi.org/10.1345/aph.1p714
- A. Christou, G., Katsiki, N., & N. Kiortsis, D. (2016, February 8). The Current Role of Liraglutide in the Pharmacotherapy of Obesity. Current Vascular Pharmacology. Bentham Science Publishers Ltd.http://doi.org/10.2174/1570161113666150615111951